Repository logo
 
Publication

European Registry on Helicobacter pylori management: Single‐capsule bismuth quadruple therapy is effective in real‐world clinical practice

dc.contributor.authorNyssen, Olga P.
dc.contributor.authorPerez‐Aisa, Angeles
dc.contributor.authorCastro‐Fernandez, Manuel
dc.contributor.authorPellicano, Rinaldo
dc.contributor.authorHuguet, Jose M.
dc.contributor.authorRodrigo, Luis
dc.contributor.authorOrtuñ, Juan
dc.contributor.authoro, null
dc.contributor.authorGomez‐Rodriguez, Blas J.
dc.contributor.authorMarcos-Pinto, Ricardo
dc.contributor.authorAreia, Miguel
dc.contributor.authorPerona, Monica
dc.contributor.authorNuñez, Oscar
dc.contributor.authorRomano, Marco
dc.contributor.authorGravina, Antonietta G.
dc.contributor.authorPozzati, Liliana
dc.contributor.authorFernandez‐Bermejo, Miguel
dc.contributor.authorVenerito, Marino
dc.contributor.authorMalfertheiner, Peter
dc.contributor.authorFernanadez‐Salazar, Luis
dc.contributor.authorGasbarrini, Antonio
dc.contributor.authorVaira, Dino
dc.contributor.authorPuig, Ignasi
dc.contributor.authorMegraud, Francis
dc.contributor.authorO'Morain, Colm
dc.contributor.authorGisbert, Javier P.
dc.date.accessioned2023-11-14T12:00:19Z
dc.date.available2023-11-14T12:00:19Z
dc.date.issued2021-02
dc.descriptionClinicalTrials.gov NCT02328131pt_PT
dc.description.abstractBackground: There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks to a three-in-one single-capsule formulation. Objective: To evaluate the effectiveness and safety of the single-capsule bismuth quadruple therapy. Methods: Data were collected in a multicentre, prospective registry of the clinical practice of gastroenterologists on the management of H. pylori infection, where patients were registered at the Asociación Española de Gastroenterologia REDCap database on an electronic case report form until January 2020. Effectiveness by modified intention-to-treat and per-protocol as well as multivariable analysis were performed. Independent factors evaluated were: age, gender, indication, compliance, proton pump inhibitor dose and treatment line. Results: Finally, 2100 patients were prescribed single-capsule bismuth quadruple therapy following the technical sheet (i.e., three capsules every 6 h for 10 days). The majority of these patients were naive (64%), with an average age of 50 years, 64% women and 16% with peptic ulcer. An overall modified intention-to-treat effectiveness of 92% was achieved. Eradication was over 90% in first-line treatment (95% modified intention-to-treat, n = 1166), and this was maintained as a rescue therapy, both in second (89% modified intention-to-treat, n = 375) and subsequent lines of therapy (third to sixth line: 92% modified intention-to-treat, n = 236). Compliance was the factor most closely associated with treatment effectiveness. Adverse events were generally mild to moderate, and 3% of patients reported a severe adverse event, leading to discontinuation of treatment in 1.7% of cases. Conclusions: Single-capsule bismuth quadruple therapy achieved H. pylori eradication in approximately 90% of patients in real-world clinical practice, both as a first-line and rescue treatment, with good compliance and a favourable safety profile.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationNyssen OP, Perez-Aisa A, Castro-Fernandez M, et al. European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice. United European Gastroenterol J. 2021;9(1):38-46. doi:10.1177/2050640620972615pt_PT
dc.identifier.doi10.1177/2050640620972615pt_PT
dc.identifier.issn2050-6406
dc.identifier.issn2050-6414
dc.identifier.urihttp://hdl.handle.net/10400.16/2887
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherWileypt_PT
dc.relation.publisherversionhttps://onlinelibrary.wiley.com/doi/10.1177/2050640620972615pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectHelicobacter pyloript_PT
dc.subjectPylerapt_PT
dc.subjectbismuthpt_PT
dc.subjecteradicationpt_PT
dc.subjectquadruplept_PT
dc.titleEuropean Registry on Helicobacter pylori management: Single‐capsule bismuth quadruple therapy is effective in real‐world clinical practicept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceEnglandpt_PT
oaire.citation.endPage46pt_PT
oaire.citation.issue1pt_PT
oaire.citation.startPage38pt_PT
oaire.citation.titleUnited European Gastroenterology Journalpt_PT
oaire.citation.volume9pt_PT
person.familyNameMarcos-Pinto
person.givenNameRicardo
person.identifier.orcid0000-0001-9695-8261
person.identifier.ridK-4612-2013
person.identifier.scopus-author-id53984773600
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication7af2c629-e150-47fc-b0e1-69831696045b
relation.isAuthorOfPublication.latestForDiscovery7af2c629-e150-47fc-b0e1-69831696045b

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Nyssen-2021-European-registry-on-helicobacter-p.pdf
Size:
263.92 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.44 KB
Format:
Item-specific license agreed upon to submission
Description: